Pharmaceutical Technology on MSN3d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
N.J. - Johnson & Johnson (NYSE:JNJ) has revealed promising overall survival (OS) results from its Phase 3 MARIPOSA study, which could transform the treatment landscape for patients with advanced ...
Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Johnson & Johnson recently experienced a 12 ... which showcased promising results in ulcerative colitis treatment. These positive results provided a boost to investor confidence amid overall ...
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback